Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

34.34 +3.65 (+11.89%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond ↗

August 19, 2025

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for something BIG."

Via Benzinga

Topics Bonds

Predicting the Next Rule Breaker Buyout ↗

August 19, 2025

Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?

Via The Motley Fool

Topics Artificial Intelligence

Why Viking Therapeutics Stock Zoomed 5% Higher Today ↗

August 18, 2025

The company is a front-runner in the race to develop an orally administered weight loss drug.

Via The Motley Fool

Earnings Scheduled For July 23, 2025 ↗

July 23, 2025

Via Benzinga

A Look Ahead: Viking Therapeutics's Earnings Forecast ↗

July 22, 2025

Via Benzinga

Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform

August 18, 2025

Via AB Newswire

1 Beaten-Down Stock That Could Soar by the End of the Year ↗

August 17, 2025

The drugmaker has a major catalyst on the way.

Via The Motley Fool

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. ↗

August 16, 2025

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.

Via The Motley Fool

Topics Economy

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst ↗

August 13, 2025

William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback.

Via Benzinga

The 3 Things That Matter for Viking Therapeutics Now ↗

August 13, 2025

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Via The Motley Fool

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today ↗

August 12, 2025

The biopharmaceutical company has an exciting lead compound in development.

Via The Motley Fool

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗

August 07, 2025

Via Stocktwits

Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98...

Via MarketMinute

Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...

Via MarketMinute

Topics Economy

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗

August 07, 2025

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Via Benzinga

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗

August 07, 2025

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Via Investor's Business Daily

Is It Time to Buy Biotech Stocks? ↗

August 06, 2025

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Via The Motley Fool

This Biotech Stock Could Soar on Upcoming Clinical Data ↗

August 04, 2025

This weight loss drugmaker may be significantly undervalued right now.

Via The Motley Fool

2 Beaten-Down Stocks With Incredible Upside Potential ↗

August 03, 2025

Getting in on the ground floor with these companies might lead to superior returns.

Via The Motley Fool

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗

August 03, 2025

These biotech businesses look compelling for very different reasons.

Via The Motley Fool

Is Viking Therapeutics the Next Big Biotech Bet? ↗

August 01, 2025

Via The Motley Fool

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets ↗

July 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 24, 2025

Via Benzinga

Viking Therapeutics Posts Wider Q2 Loss ↗

July 23, 2025

Via The Motley Fool

Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates ↗

July 23, 2025

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter.

Via Benzinga

Viking (VKTX) Q2 2025 Earnings Call Transcript ↗

July 23, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 23, 2025

Via Benzinga

Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading ↗

July 23, 2025

Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges.

Via Chartmill

Better Growth Buy: Eli Lilly vs. Viking Therapeutics ↗

July 22, 2025

Via The Motley Fool

3 Monster Stocks in the Making to Buy Right Now ↗

July 21, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.